Toshikazu Ikuta

Dr. Toshikazu Ikuta

Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, Oxford, MS, USA
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
DSDeepak K. Sarpal
Deepak K. Sarpal
DRDelbert G. Robinson
Delbert G. Robinson
TLTodd Lencz
Todd Lencz
MAMiklos Argyelan
Miklos Argyelan
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
AMAnil K. Malhotra
Anil K. Malhotra
Disruptions in corticostriatal circuitry have been implicated in the pathophysiology of schizophrenia. Early proposals linked schizophrenia with decreases in dopamine in the prefrontal cortex and excessive dopamine in the striatum.1,2 Although elevated striatal dopamine has been shown in patients with schizophrenia,3 their unaffected relatives,4 and individuals who are at risk for developing psychotic symptoms,5 corticostriatal relationships have also been demonstrated to play a central role in psychosis. Early positron emission tomography work found that the severity of psychotic symptoms correlated with abnormal patterns of blood flow in limbic and prefrontal cortical regions.6 Studies in schizophrenia using functional magnetic resonance imaging (fMRI) have reported abnormal corticostriatal activation during reward7,8 and executive processing.9,10 Evidence from functional connectivity and multimodal studies have shown altered corticostriatal circuitry in patients with chronic schizophrenia11,12 and in patients with prodromal psychotic symptoms.13,14 A previous family-based study suggested that altered functional connectivity between striatum and cortical regions may represent a risk phenotype in patients with first-episode psychosis (FEP) and their relatives.15

18 September 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
TKTaro Kishi
Taro Kishi
SMShinji Matsunaga
Shinji Matsunaga
KOKazuto Oya
Kazuto Oya
INIkuo Nomura
Ikuo Nomura
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
NINakao Iwata
Nakao Iwata
Background: The clinical benefit of memantine for Alzheimer’s disease (AD) remains inconclusive. Objective: We performed an updated systematic review and meta-analysis of the efficacy/safety of memantine in AD. Methods: We included randomized trials of memantine for AD patients. Cognitive function scores (CF), behavioral disturbances scores (BD), and all-cause discontinuation were used as primary measures. Effect size based on a random-effects model was evaluated in the meta-analyses. Results: Thirty studies ( n = 7,567; memantine versus placebo: N = 11, n = 3,298; memantine + cholinesterase inhibitors (M+ChEIs) versus ChEIs: N = 17, n = 4,175) were identified. Memantine showed a significant improvement in CF [standardized mean difference (SMD) = –0.24, 95% confidence intervals (95% CIs) = –0.34, –0.15, p < 0.00001, I 2 = 35% ] and BD (SMD = –0.16, 95% CIs = –0.29, –0.04, p = 0.01, I 2 = 52%) compared with placebo. In the sensitivity analysis including only patients with moderate–severe AD, memantine was superior to the placebo in reducing BD without considerable heterogeneity (SMD = –0.20, 95% CIs = –0.34, –0.07, p = 0.003, I 2 = 36%). Compared with ChEIs, M+ChEIs showed a greater reduction in BD (SMD = –0.20, 95% CIs = –0.36, –0.03, p = 0.02, I 2 = 77%) and a trend of CF improvement (SMD = –0.11, 95% CIs = –0.22, 0.01, p = 0.06, I 2 = 56%). However, in the sensitivity analysis of double-blind, placebo-controlled studies only, M+ChEIs showed a significant reduction in BD compared with ChEIs without considerable heterogeneity (SMD = –0.11, 95% CIs = –0.21, –0.01, p = 0.04, I 2 = 40%). When performing the sensitivity analysis of donepezil studies only, M+ChEIs was superior to ChEIs in improving CF without considerable heterogeneity (SMD = –0.18, 95% CIs = –0.31, –0.05, p = 0.006, I 2 = 49%). No differences were detected in all-cause discontinuation between the groups. Conclusions: The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.

12 April 2012 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
BPBart D. Peters
Bart D. Peters
PSPhilip R. Szeszko
Philip R. Szeszko
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
PGPatricia Gruner
Patricia Gruner
AMAnil K. Malhotra
Anil K. Malhotra
Background In light of the evidence for brain white matter (WM) abnormalities in schizophrenia, study of normal WM maturation in adolescence may provide critical insights relevant to the neurodevelopment of the disorder. Voxel-wise diffusion tensor imaging (DTI) studies have consistently demonstrated increases in fractional anisotropy (FA), a putative measure of WM integrity, from childhood into adolescence. However, the WM tracts that show FA increases have been variable across studies. Here, we aimed to assess which WM tracts show the most pronounced changes across adolescence. Methods DTI was performed in 78 healthy subjects aged 8–21 years, and voxel-wise analysis conducted using tract-based spatial statistics (TBSS). In addition, we performed the first meta-analysis of TBSS studies on WM development in adolescence. Results In our sample, we observed bilateral increases in FA with age, which were most significant in the left superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, and anterior thalamic radiation. These findings were confirmed by the meta-analysis, and FA increase in the bilateral SLF was the most consistent finding across studies. Moreover, in our sample, FA of the bilateral SLF showed a positive association with verbal working memory performance and partially mediated increases in verbal fluency as a function of increasing age. Conclusions These data highlight increasing connectivity in the SLF during adolescence. In light of evidence for compromised SLF integrity in high-risk and first-episode patients, these data suggest that abnormal maturation of the SLF during adolescence may be a key target in the neurodevelopment of schizophrenia.

17 January 2018 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
TKTaro Kishi
Taro Kishi
RYReiji Yoshimura
Reiji Yoshimura
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
NINakao Iwata
Nakao Iwata
Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.

1 February 2014 in Biological Psychiatry
Verified
Journal Article
Closed access
BPBart D. Peters
Bart D. Peters
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
PDPamela DeRosse
Pamela DeRosse
MJMajnu John
Majnu John
KBKatherine E. Burdick
Katherine E. Burdick
AMAnil K. Malhotra
Anil K. Malhotra

16 October 2013 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PSPhilip R Szeszko
Philip R Szeszko
DRDelbert G Robinson
Delbert G Robinson
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
BPBart D Peters
Bart D Peters
JGJuan A Gallego
Juan A Gallego
AMAnil K Malhotra
Anil K Malhotra